Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Patent Rule Limits Applications, Impacting Device Makers’ Filing Strategies

This article was originally published in The Gray Sheet

Executive Summary

A highly anticipated final 1rule from the U.S. Patent and Trademark Office puts new limits on the number of applications a company can file for any single invention, potentially requiring changes in device manufacturers' patent strategies

You may also be interested in...



Rule Limiting Patent Application Filings Is Officially Off The Table

The U.S. Patent and Trademark Office rescinded a set of controversial regulations intended to cap certain patent application filings in a revised final 1rule released Oct. 14

Rule Limiting Patent Application Filings Is Officially Off The Table

The U.S. Patent and Trademark Office rescinded a set of controversial regulations intended to cap certain patent application filings in a revised final 1rule released Oct. 14

Industry Takes Round 1 In Patent Office Rule Dispute, Gets Temporary Hold

GlaxoSmithKline won a reprieve for life science industries when a federal court agreed to temporarily halt implementation of new patent rules that would have limited the number of continuation applications a patent holder can file

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT025185

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel